デフォルト表紙
市場調査レポート
商品コード
1462893

消化器疾患関連の事業協力・ライセンス取引 (2016~2024年)

Gastrointestinal Collaboration and Licensing Deals 2016-2024

出版日: | 発行: Current Partnering | ページ情報: 英文 250+ Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.74円
消化器疾患関連の事業協力・ライセンス取引 (2016~2024年)
出版日: 2024年04月01日
発行: Current Partnering
ページ情報: 英文 250+ Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、消化器疾患の治療薬開発に関する昨今 (2016~2024年) の事業協力・ライセンス取引の取引動向について分析し、全体的な取引形成件数の推移や、財務面 (支払条件) での傾向、主要企業による取引形成の動き、契約条件の傾向、適応症別 (治療標的別) の傾向などを調査すると共に、近年の主要な提携取引の詳細情報を取りまとめてお届けいたします。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 消化器疾患関連の取引形成の傾向

  • イントロダクション
  • 消化器疾患関連の取引形成:長期的動向
  • 消化器疾患関連の取引形成:取引の種類別
  • 消化器疾患関連の取引形成:業界別
  • 消化器疾患関連の取引形成:開発段階別
  • 消化器疾患関連の取引形成:技術の種類別
  • 消化器疾患関連の取引形成:適応症別

第3章 消化器疾患関連の事業提携:財務面での条件

  • イントロダクション
  • 消化器疾患関連の事業提携の開示されている財政的条件
  • 消化器疾患関連の事業提携:取引総額
  • 消化器疾患関連の事業提携:前払い金
  • 消化器疾患関連の事業提携:マイルストーン払い
  • 消化器疾患関連の事業提携:ロイヤルティ率

第4章 消化器疾患関連の主な取引先と取引

  • イントロダクション
  • 消化器疾患関連の提携で最も活動的な企業
  • 消化器疾患関連で最も活動的な企業の一覧
  • 消化器疾患関連の主要な取引:契約金額別

第5章 消化器疾患の契約文書ディレクトリ

  • イントロダクション
  • 消化器疾患関連の資本取引の動向:契約文章が閲覧可能な取引の場合

第6章 消化器疾患関連の取引形成:治療標的別

  • イントロダクション
  • 消化器疾患関連の取引形成:治療標的別
  • 取引一覧
  • 消化器疾患関連の取引一覧、企業名別 (ABC順、2016~2024年)
  • 消化器疾患関連の取引一覧、技術の種類別 (2016~2024年)
  • 取引の種類の定義
  • Biopharma Research Ltd. について
  • 現在の提携
  • 現在の契約
  • Current Partneringからの最近のレポートタイトル
目次
Product Code: CP2214

Gastrointestinal Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gastrointestinal deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 380 gastrointestinal deals from 2016 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of gastrointestinal dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in gastrointestinal dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the gastrointestinal field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in gastrointestinal dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of gastrointestinal deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of gastrointestinal deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in gastrointestinal deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Gastrointestinal Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse gastrointestinal collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

  • Gastrointestinal Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gastrointestinal trends and structure of deals entered into by leading biopharma companies worldwide.

Gastrointestinal Collaboration and Licensing Deals includes:

  • Trends in gastrointestinal dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of gastrointestinal deal records covering pharmaceutical and biotechnology
  • The leading gastrointestinal deals by value
  • Most active gastrointestinal licensing dealmakers

In Gastrointestinal Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type
  • Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
  • Gastrointestinal Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gastrointestinal dealmaking

  • 2.1. Introduction
  • 2.2. Gastrointestinal partnering over the years
  • 2.3. Gastrointestinal partnering by deal type
  • 2.4. Gastrointestinal partnering by industry sector
  • 2.5. Gastrointestinal partnering by stage of development
  • 2.6. Gastrointestinal partnering by technology type
  • 2.7. Gastrointestinal partnering by therapeutic indication

Chapter 3 - Financial deal terms for gastrointestinal partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for gastrointestinal partnering
  • 3.3. Gastrointestinal partnering headline values
  • 3.4. Gastrointestinal deal upfront payments
  • 3.5. Gastrointestinal deal milestone payments
  • 3.6. Gastrointestinal royalty rates

Chapter 4 - Leading gastrointestinal deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in gastrointestinal partnering
  • 4.3. List of most active dealmakers in gastrointestinal
  • 4.4. Top gastrointestinal deals by value

Chapter 5 - Gastrointestinal contract document directory

  • 5.1. Introduction
  • 5.2. Gastrointestinal partnering deals where contract document available

Chapter 6 - Gastrointestinal dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by gastrointestinal therapeutic target
  • Deal directory
  • Deal directory - Gastrointestinal deals by company A-Z 2016 to 2024
  • Deal directory - Gastrointestinal deals by technology type 2016 to 2024
  • Deal type definitions
  • About Biopharma Research Ltd
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Gastrointestinal partnering since 2016
  • Figure 2: Gastrointestinal partnering by deal type since 2016
  • Figure 3: Gastrointestinal partnering by industry sector since 2016
  • Figure 4: Gastrointestinal partnering by stage of development since 2016
  • Figure 5: Gastrointestinal partnering by technology type since 2016
  • Figure 6: Gastrointestinal partnering by indication since 2016
  • Figure 7: Gastrointestinal deals with a headline value
  • Figure 8: Gastrointestinal deals with upfront payment values
  • Figure 9: Gastrointestinal deals with milestone payment
  • Figure 10: Gastrointestinal deals with royalty rates
  • Figure 11: Active gastrointestinal dealmaking activity since 2016
  • Figure 12: Top gastrointestinal deals by value since 2016